Health AI Central
Share:
Peer-Reviewed Publication
Sci Rep2026;16(1)March 23, 2026Journal Article

Monitoring treatment response using an ultra-sensitive ctDNA assay in advanced esophagogastric cancer patients.

Andrew B Nixon1, Fábio C P Navarro2, Katherine I Zhou3, Charles W Abbott2, Lee McDaniel2, Neeraja Ravi2, Lauren E Howard4, J Christopher Brady3, Yingmiao Liu3, Jingquan Jia5, Donna Niedzwiecki4, John H Strickler3, Sean M Boyle2, Richard O Chen2, Hope Uronis3
1Department of Medicine, Duke University Medical Center, Box 2631, Durham, NC, 27710, USA. anixon@duke.edu.
2Personalis Inc, Menlo Park, CA, USA.
3Department of Medicine, Duke University Medical Center, Box 2631, Durham, NC, 27710, USA.
4Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA.
5Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
PubMed PMC DOI PDF

Abstract

To explore whether ultra-sensitive circulating tumor DNA (ctDNA) profiling enables earlier prediction of treatment response and detection of disease progression, we applied NeXT Personal, an ultra-sensitive bespoke tumor-informed liquid biopsy platform, to profile tumor samples from the KeyLargo study, a phase II trial in which metastatic esophagogastric cancer (mEGC) patients received capecitabin…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.